A month after making a similar decision for the Pfizer shot, an expert committee on Thursday recommended a booster dose of Moderna’s anti-Covid vaccine for certain at-risk groups in the United States.
The opinion presented by the Food and Drug Administration’s advisory committee — made up of researchers, epidemiologists and infectious disease experts — is not binding, but it is rare for the FDA not to comply.
After a day of debate, experts decided to authorize a booster dose of Moderna for three categories of people: people over the age of 65, people between the ages of 18 and 64 who are at high risk of developing a severe version of the coronavirus. are at risk, and those whose work may involve repeated exposure to the virus.
The same definition was adopted for the Pfizer booster.
The last category includes supermarket workers, health workers, prisoners and people in homeless shelters.
A booster can be given six months after the second injection of Moderna’s vaccine. The dosage is 50 micrograms, which is half the dose of the initial shots.
A representative for Moderna told the panel that the booster would help counter the delta variant, at a time when the vaccine’s effectiveness has been shown to decline over time against mild cases of infection and disease, even though it does not work against severe cases. remains effective.
The committee will meet again on Friday to give its decision on a booster dose for the Johnson & Johnson vaccine.
It will also discuss the results of a study published this week that looked at the possibility of using a different vaccine for the booster shot than that used for the initial dose, which is not authorized in the United States at this time. Is.
The study suggests that people who have received the Johnson & Johnson vaccine may benefit from a booster dose of a different, messenger-RNA vaccine, such as Pfizer or Moderna.
About 15 million Americans have received a single dose of the J&J vaccine, and about 70 million have been fully vaccinated from Moderna.
If the FDA officially allows booster shots for these two vaccines, an expert committee from the Centers for Disease Prevention and Control (CDC) will have to give its opinion at a meeting on Wednesday and Thursday next week.
As a final step, the CDC must publish precise recommendations for these injections, which are intended to be administered to health care professionals.
(This story has not been edited by NDTV staff and is auto-generated from a syndicated feed.)